Piper Sandler restated their neutral rating on shares of Xeris Biopharma (NASDAQ:XERS - Free Report) in a research note issued to investors on Friday morning, MarketBeat.com reports. They currently have a $4.00 target price on the stock, up from their previous target price of $3.00.
A number of other brokerages have also recently commented on XERS. HC Wainwright reiterated a "buy" rating and issued a $8.00 price target (up from $6.60) on shares of Xeris Biopharma in a research note on Friday. Jefferies Financial Group reissued a "buy" rating and set a $6.00 price target (up from $4.00) on shares of Xeris Biopharma in a research note on Wednesday, January 29th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $5.92.
Check Out Our Latest Stock Analysis on XERS
Xeris Biopharma Stock Performance
Shares of Xeris Biopharma stock traded down $0.20 during midday trading on Friday, hitting $4.39. 4,430,709 shares of the company traded hands, compared to its average volume of 2,084,559. The firm's fifty day moving average price is $3.61 and its 200-day moving average price is $3.28. The stock has a market cap of $654.47 million, a price-to-earnings ratio of -9.76 and a beta of 2.32. Xeris Biopharma has a 12 month low of $1.69 and a 12 month high of $4.68.
Institutional Investors Weigh In On Xeris Biopharma
Institutional investors have recently modified their holdings of the company. Wealth Enhancement Advisory Services LLC bought a new stake in Xeris Biopharma during the third quarter valued at $35,000. Connor Clark & Lunn Investment Management Ltd. acquired a new stake in Xeris Biopharma during the third quarter worth approximately $237,000. Intech Investment Management LLC bought a new stake in Xeris Biopharma in the third quarter worth approximately $130,000. Quantbot Technologies LP acquired a new position in Xeris Biopharma in the third quarter valued at approximately $44,000. Finally, Walleye Capital LLC bought a new position in shares of Xeris Biopharma during the 3rd quarter worth approximately $3,197,000. 42.75% of the stock is owned by institutional investors.
About Xeris Biopharma
(
Get Free Report)
Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.
Further Reading
Before you consider Xeris Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Xeris Biopharma wasn't on the list.
While Xeris Biopharma currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
